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In vivoises a diverse array of neuronal cell-surface proteins of the cadherin superfamily,
although very little is known about their role in neural development. Here we provide the ﬁrst in-depth
characterization of pcdh1α in zebraﬁsh. Whole-mount immunocytochemistry demonstrates that a large
proportion of endogenous cytoplasmic domain immunoreactivity is present in the nucleus, suggesting that
endoproteolytic cleavage and nuclear translocation of the intracellular domain are important aspects of pcdh1α
activity in vivo. Using whole-mount immunocytochemistry and BAC-based expression of Pcdh1α-GFP fusion
proteins,weﬁnd that Pcdh1αdoesnot appear to formstable, synapticpuncta at early stagesof synaptogenesis.We
alsodemonstrate that the presence of the Pcdh1α cytoplasmic domain is essential for normal function. Truncation
of Pcdh1α proteins, using splice-blocking antisense morpholinos to prevent the addition of the common
intracellular domain to the entire pcdh1α cluster, results in neuronal apoptosis throughout the developing brain
and spinal cord, demonstrating an essential role forpcdh1α in early neural development. This cell deathphenotype
can be attenuated by the expression of a soluble Pcdh1α cytoplasmic domain.
© 2008 Elsevier Inc. All rights reserved.IntroductionIn mammals, the clustered protocadherins (pcdhs) comprise three
tandemly-arrayed genes of cadherin-like cell surface receptors,
pcdhα, pcdhβ and pcdhγ, encoding over 50 distinct proteins (Sugino
et al., 2000; Wu and Maniatis, 1999; Wu et al., 2001; Zou et al., 2007).
The pcdhα and pcdhγ genes are notable for their organization into
sets of 5′ variable exons, each encoding the entire extracellular and
transmembrane domains, and three 3′ constant exons that encode a
common cytoplasmic domain (Wu and Maniatis, 1999). Each variable
exon is expressed under the control of its own promoter, which is
then spliced to the constant exons to generate a full-length protein
(Tasic et al., 2002; Wang et al., 2002a). The clustered protocadherins
are expressed predominantly in neurons (Kohmura et al., 1998; Wang
et al., 2002b; Zou et al., 2007) and, within a brain region, individual
neurons express only a small subset of protocadherin isoforms
(Esumi et al., 2005; Kaneko et al., 2006; Kohmura et al., 1998; Wang
et al., 2002b; Zou et al., 2007). Due to these observations, it has been
widely hypothesized that the clustered protocadherins may con-
tribute to a molecular code for synaptic connectivity (Hilschmann et
al., 2001; Redies et al., 2003; Shapiro and Colman, 1999; Suzuki,
2000). However, there is little direct evidence to support this
hypothesis, and the speciﬁc biological functions of these genes are
not known.l rights reserved.The cell biology of Pcdhα and the role of Pcdhα in neural
development are poorly understood. These proteins were ﬁrst discov-
ered on the basis of a yeast 2-hybrid screen for Fyn kinase-interacting
proteins (Kohmura et al., 1998). Pcdhα protein has been shown to be
present in developing axons (Blank et al., 2004; Morishita et al., 2004a;
Morishita et al., 2004b). In contrast to expectations, Pcdhα isoforms
exhibit little cell–cell adhesion (Morishita et al., 2006; Triana-Baltzer and
Blank, 2006). Recently, Pcdhα has been shown to undergo sequential
proteolytic processing by matrix metalloproteases (MMPs) and Pre-
senilin-1 when expressed in heterologous cells (Bonn et al., 2007). The
carboxy-terminal intracellular domain is released as a soluble fragment,
which is capable of translocating to the nucleus. However, the fraction of
Pcdhα undergoing proteolysis appears relatively low, and the in vivo
signiﬁcance of these observations is uncertain.
While no functional data for the pcdhα gene are presently
available, some information is available for the pcdhγ gene, coming
from studies of mice in which pcdhγ has been deleted (Wang et al.,
2002b; Weiner et al., 2005). These mice die shortly after birth,
exhibiting extensive apoptosis of spinal interneurons (Wang et al.,
2002b). More detailed analysis has also revealed synaptic deﬁcits,
although neither the cell biological roles played by Pcdhγ, nor the
relationship of the synaptic deﬁcits to the observed cell death, have
been determined (Weiner et al., 2005).
As the zebraﬁsh has a highly stereotyped and relatively simple
embryonic nervous system, it offers an excellent opportunity to
investigate the role of protocadherins in neural development. Here we
focus on pcdh1α, providing the ﬁrst in vivo analysis of this gene in
zebraﬁsh. We characterize the expression of pcdh1α, as well as the
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tochemistry and in vivo 2-photon time-lapse microscopy of Pcdhα-GFP
fusion proteins. In addition, we demonstrate that loss of pcdh1α activity
results in a dramatic increase in programmed cell death throughout the
nervous system, which can be partially attenuated by expression of a
soluble cytoplasmic domain fragment.
Materials and methods
Fish maintenance
Adult zebraﬁsh (Danio rerio) and embryos of the Tübingen longﬁn
and AB⁎ strains were maintained at ~28.5 °C and staged according to
Westerﬁeld (1995). Embryos were raised in E3 embryo medium
(Westerﬁeld, 1995) with 0.003% phenylthiourea (Sigma-Aldrich) to
inhibit pigment formation.
Whole-mount in situ hybridization
The constant cytoplasmic domains of pcdh1α and pcdh2α were
cloned by RT-PCR and sequenced. A T7 RNA Polymerase binding site
was added to the antisense strand by PCR and this PCR product was
used as template for in vitro transcription reactions (Promega).
Antisense riboprobe was labeled with DIG-dUTP (Roche Applied
Science) and puriﬁed on ProbeQuant G-50 spin columns (Amersham
Biosciences). Embryos were ﬁxed at 4 °C overnight in 4% paraformal-
dehyde in PBS, permeabilized in methanol at −20°C overnight,
rehydrated, treated with proteinase K (10 μg/ml, Roche Applied
Science), and reﬁxed in 4% paraformaldehyde prior to hybridization.
Labeled riboprobewas added to a ﬁnal concentration of 400 ng/ml and
hybridization occurred overnight at 65 °C. AP-conjugated anti-DIG Fab
fragments (Roche Applied Science) were used at 1:5000, and the in
situs were developed with NBT/BCIP (Roche Applied Science).
BAC recombineering and DNA injections
BAC recombineering
The BAC clone CH211-150p9 (Accession # AC144823) was obtained
from BACPAC Resources (http://bacpac.chori.org). BAC DNA was
introduced into EL250 cells (obtained from N. Copeland, NIH), to
generate EL150p9 cells. EL150p9 cells were grown to midlog phase at
32 °C, induced at 42 °C for 15 min, chilled rapidly, and washed twice
with ice-cold sterile H2O. Linear targeting contructs (200–300 ng)
were electroporated into electrocompetent EL150p9 cells and plated
after a 1 h recovery. Recombinants were grown on kanamycin
selective plates, and colonies were screened by PCR. Recombinant
BAC DNA was puriﬁed using Nucleobond AX-100 columns (Clontech
Laboratories). Puriﬁed BAC DNA was diluted in 0.1 M KCl and injected
at a concentration of 100–200 ng into 1-cell stage embryos.
Targeting construct
The constant cytoplasmic domain (CD) of the pcdh1α cluster was
ampliﬁed from cDNA by PCR and subcloned into pEGFP-N1 (Clontech
Laboratories) using EcoRI andAgeI sites (whichwere included in the PCR
primers). The resulting Pcdh1αCD-GFP fusion was sequenced. PCR
primers were made which ampliﬁed the Pcdh1αCD fusion protein and
the downstream kanamycin selection marker, and contained 60 base
pairs of homology to the targeted BAC. The 5'-primer was designed to
place the Pcdh1αCD-GFP in register with the replaced constant exon 1,
thus preserving the splice acceptor site and its relationship to the αCD.
Morpholino and mRNA injections
Antisense morpholino oligonucleotides were purchased from
Gene-Tools LLC. The morpholinos were dissolved in dH2O at ~8 ng/
nl, aliquoted and stored at −80°C. For use, morpholinos were diluted toa working concentration of 2–4 ng/nl in dH2O and 1 nl was injected
into 1-cell stage embryos. For the mRNA experiments, we injected
200 pg of mRNA encoding a soluble myc-tagged Pcdh1α cytoplasmic
domain, which was inserted into pCS2+ and synthesized with an SP6
mMessage mMachine kit (Ambion). The mRNA injection experiments
were performed double-blind.
Morpholinos used in this study were the following:
MO1.1: 5′AAACTGCTTACCTCTGCACTCCTGC3′;
MO1.2 5′CTGCTTACCTCTGCACTCCTGCCCT3′;
MO1.1mis 5′AATCTCCTTAGCTCTGGACTCGTGC3′;
MO1.2mis 5′CTCCTTAGCTCTCCACTCGTGCCCT3′;
p53MO 5′GCGCCATTGCTTTGCAAGAATTG3′;
MO2.1 5′AACTATCTTACCAGGAGCGCTGGAA3′
MO2.2 5′AAGTCTTACCTTTGCATTCCTGCTC3′
MO2.2mis 5′AACTCTTAGCTTTCCATTCGTGGTC3′
Time-lapse imaging and analysis
Imaging
GFP-labeled embryos were mounted in 1.5% low melting point
agarose and placed on a custom-built laser-scanning two-photon
microscope. Excitation was provided by a Chameleon-XR Ti:Sapphire
laser (Coherent, Inc.), tuned to 920 nm. We used a Zeiss 63× Achroplan-
IR NA 0.9 objective (Carl Zeiss Microimaging) for imaging. The software
for control of the microscope was very kindly provided by Dr. Noam Ziv
(Technion, Haifa, Israel). Images were scanned with a pixel size of
0.22 μm. Time-lapse sequences consisted of image stacks of 15–25
optical sections at 1 μm spacing, collected at 2 min intervals for 2–24 h.
Image processing was performed using ImageJ (http://rsb.info.nih.gov/
ij). For presentation purposes, regions of interest were cropped and the
image contrast was inverted and adjusted in Adobe Photoshop.
Generation of polyclonal Pcdh1αCD antibody
Antibodies were produced against the common cytoplasmic
domain of the zebraﬁsh Pcdh1α cluster (Pcdh1αCD). Rabbits were
immunized against a GST-fusion protein (GST-Pcdh1αCD) and afﬁnity
puriﬁcation was performed using an MBP-fusion (MBP-Pcdh1αCD;
Covance Research Products).
Whole-mount immunocytochemistry
Embryos were ﬁxed overnight in 4% paraformaldehyde, permea-
bilized in 1% TX-100 in PBS for 1 h and blocked for 1 h in PBS
containing 1% dimethylsulfoxide, 2 mg/ml BSA, 0.2% Triton X-100, and
5% normal goat serum. Antibody was added at a dilution of 1:100
(Pcdh1α-CD), 1:1000 (acetylated tubulin; Sigma-Aldrich), 1:500 (SV2;
DSHB) or 1:500 (myc; Sigma-Aldrich) and incubated overnight at 4 °C.
Rhodamine-conjugated secondary antibodies (Jackson ImmunoRe-
search) were used at a dilution of 1:500. In some experiments, DAPI
(4,6-diamidino-2-phenylindole; Sigma-Aldrich) was added with
secondary antibody at 100 ng/mL to label nuclei. Embryos were
embedded in 1.5% agarose and imaged on a two-photonmicroscope. A
myc-epitope was added to the carboxy-terminus of the constant
cytoplasmic domain and was subcloned into a UAS vector. The UAS:
myc-pcdh1αCD was expressed by co-injection with a goldﬁsh α1-
tubulin promoter:Gal4VP16 driver plasmid, and the embryos were
processed for myc immunoreactivity as described above. Statistical
analysis was performed using a Student's t-test.
HEK293 cell culture, transfection, and immunostaining
Human embryonic kidney (HEK293) cells were maintained in
DMEM supplemented with 10% FBS and penicillin-streptomycin at
37°C in 5% CO2. One day before transfection, cells were split and plated
Fig. 1. Pcdh1α is expressed in the early zebraﬁsh nervous system. (A) Genomic organization of the two pcdhα genes. Most of this study is concerned with the pcdh1α gene. (B) RT-PCR
with primers directed against the common cytoplasmic domain reveals the time-course of pcdh1α expression during development. Onset of expression occurs at ~12 hpf, increases
steadily for the ﬁrst 3 days, then remains highly expressed. (C) Shown here is a 24 hpf embryo labeled with riboprobe against the constant cytoplasmic domain of the pcdh1α gene.
Expression is conﬁned to the developing nervous system. (D) Shown here is a lateral view of a brain dissected from a 24 hpf embryo. In the forebrain, expression is present in both the
telencephalon and diencephalon. Expression is also found in the ventral midbrain, and in segmental clusters of cells in the hindbrain. In addition, pcdh1α is expressed in ephiphysial
neurons. (E) In a dorsal view of the hindbrain, rhombomeric expression is revealed by ladder-like clusters of neurons. In addition, peripheral neurons also exhibit expression,
including the trigeminal ganglion neurons, acoustico-vestibular neurons and neurons of the posterior lateral line ganglion. (F) Riboprobe against pcdh1α labels neurons throughout
the developing spinal cord. (G and H) By 48 hpf, pcdh1α expression has expanded and has become very strong throughout the developing brain, including the tectum and cerebellum.
In addition, staining can be seen in the retina. A/V, acoustico-vestibular; cb, cerebellum; di, diencephalon; ep, epiphysis; hb, hindbrain; hy, hypothalamus; pLLg, posterior lateral line
ganglion; r2-r6, rhomobomeres 2–6; ret, retina; SC, spinal cord; tec, tectum; teg, tegmentum; tel, telencephalon; Tg, trigeminal ganglion.
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performed using Lipofectamine 2000 and carried out according to the
manufacturer's instructions (Invitrogen). Cells were transiently trans-
fected with CMV::Pcdh1αCD-GFP. 24 h after transfection, cells were
ﬁxed in 4% paraformaldehyde in PBS, permeabilized in PBS+ 0.25%
Triton X-100, and blocked in PBS+ 3% BSA+ 2% NGS. The Pcdh1α-CD
antibody was used at a dilution of 1:250 in block solution and an anti-
rabbit-rhodamine secondary antibody (Jackson ImmunoResearch)was
used at 1:500. Coverslips were mounted in Fluoromount G (Electron
Microscopy Sciences) and imaged on a Zeiss Axiostar microscope
(Carl Zeiss Microimaging).
Western blot analysis
Proteins were extracted from 24–72 hpf zebraﬁsh embryos using
homogenization buffer (50 mM Tris–HCl pH 6.8, 10% SDS, 10 mM
EDTA, Mini Complete EDTA-free Protease inhibitor cocktail (RocheApplied Science)). Extracts were boiled for 10 min, microcentrifuged
at 4 °C for 10 min, and the supernatant reserved. Protein concentra-
tion was determined using the Bradford Assay (Bio-Rad). Sample
buffer was added to the extracts, which were then heated to 70 °C for
10 min, and 50 μg/ml total protein/lane was loaded onto 10% Bis–Tris
NuPAGE gels (Invitrogen). Equal loading of lanes was assessed by
Coomassie staining. Proteins were transferred (Bio-Rad) onto
nitrocellulose membranes (GE Healthcare), blocked in TBST+ 7%
nonfat milk, and incubated in block with Pcdh1α-CD antibody at
1:800. An anti-rabbit-HRP secondary antibody (Jackson ImmunoR-
esearch) was used at 1:5000 and the chemiluminescent signal was
ampliﬁed using Western Lightning (Perkin Elmer). Blots were imaged
on an Omega 12iC Molecular Imaging System (UltraLum, Inc.), and
were analyzed using ImageJ. For Western blotting of HEK293 cell
extracts, cells were washed in PBS and lysed in TBS+ 0.5% Triton X-
100 24 h after transfection. Samples were subjected to SDS-PAGE as
described above.
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Acridine orange staining
A stock solution of acridine orange (Sigma-Aldrich) was made at
10 mg/ml in dimethylsulfoxide. For staining embryos, the stock
solution was diluted 1:5000 in E3 embryo medium (Westerﬁeld,
1995). Embryos were soaked in this working solution for 30–60 min
before washing and imaging on ﬂuorescence stereomicroscope (Leica
MZ16F; Leica Microsystems). Statistical analysis was performed using
a Student's t-test.
TUNEL labeling
Embryos were ﬁxed in 4% paraformaldehyde in PBS and permea-
bilized in methanol at −20 °C. TUNEL labeling was performed using
ﬂuorescein-dUTP and terminal deoxytransferase (Roche Applied
Science). Embyros were incubated with 1:2500 dilution of alkaline-
phosphatase conjugated anti-ﬂuorescein Fab fragments (Roche
Applied Science), and the colorimetric reaction was performed using
NBT/BCIP substrate (Roche Applied Science).
Results
Neuronal expression of pcdh1α
In contrast to mammals, zebraﬁsh possess two pcdhα genes
(pcdh1α and pcdh2α), comprising 45 distinct isoforms (Noonan et
al., 2004; Tada et al., 2004; Wu, 2005): 10 encoded by pcdh1α on
chromosome 10, and 35 encoded by pcdh2α on chromosome 14 (Fig.
1a). To characterize the zebraﬁsh pcdh1α gene, we ﬁrst determined
the time-course of expression during development. Using RT-PCR, we
were ﬁrst able to detect pcdh1α transcript by 12 h postfertilization
(hpf; Fig. 1b). The level of pcdh1α expression steadily increased during
the ﬁrst 3 days of development and remained highly expressed
thereafter. We next performed whole-mount in situ hybridization
using riboprobes against the constant cytoplasmic domain sequences
of either pcdh1α or pcdh2α, which is common to all isoforms in the
respective cluster. Expression patterns for pcdh1α and pcdh2α were
similar, and we only present data for pcdh1α. At 24 hpf, pcdh1α is
expressed throughout the developing CNS (Fig. 1c; Bass et al., 2007).
Expression is observed in the telencephalon and the diencephalon, as
well as the ventral midbrain (Fig. 1d). A ladder-like array of labeled
neurons in the hindbrain demarcates the rhombomeric organization
of the hindbrain (Figs. 1d, e). Additionally, neurons in the peripheral
nervous system are also labeled, including trigeminal ganglion
neurons, neurons of the posterior lateral line ganglion and acous-
tico-vestibular neurons (Fig. 1e). In the spinal cord, there is extensive
labeling of neurons (Figs.1c, f). By 48 hpf, the expression of the pcdh1α
genes increases dramatically, with strong labeling throughout the CNS
(Figs. 1g, h), as well as the retina (Fig. 1h).
Distribution of Pcdh1α protein
To characterize the distribution of Pcdh1α protein, we generated a
rabbit polyclonal antibody against the constant cytoplasmic domain
of Pcdh1α (Pcdh1αCD). To test the speciﬁcity of the antibody, we
prepared cell extracts from HEK293 cells transfected with a
membrane associated Pcdh1α cytoplasmic domain-GFP fusion pro-
tein and performed Western blotting (Fig. 2a, lanes 1 and 2). The
antibody recognizes a major band of the predicted size of ~76 kDa
(lane 2). No bands are detected in extracts prepared from untrans-
fected cells (lane 1). Western blots of protein extracts prepared from
72 hpf embryos exhibited two major bands of ~105 kDa (Fig. 2a, lane
3), the approximate, predicted molecular mass of zebraﬁsh CNR/
Pcdh1α proteins. Immunocytochemistry shows that the antibody
labels HEK293 cells transfected with the GFP-fusion protein, while
untransfected cells, present in the same ﬁeld, do not exhibit antibodylabeling (Fig. 2b). Thus, our antibody recognizes the Pcdh1α
cytoplasmic domain.
In 24 hpf embryos, whole-mount immunolabeling of Pcdh1α
revealed a wide distribution in neurons of the developing nervous
system, consistent with the expression patterns determined by in situ
hybridization (Figs. 2c–h). The Pcdh1αCD antibody stained the early
scaffold of axon tracts in the brain, as well as early clusters of neurons
(Fig. 2c). In the hindbrain, a ladder-like array of neurons was labeled
(Fig. 2d, e), as well as ventral axon tracts and peripheral sensory
neurons (Fig. 2d). In the spinal cord, axons present in the lateral
marginal zone were labeled, as were postmitotic neurons present in
the mantle layer (Figs. 2f–h). Interestingly, it appears that Pcdh1α is
expressed very early in neurons, as labeled cells close to the ventral
midline are also observed (Fig. 2g). Often, these are observed as
symmetric pairs of cells across the midline, reminiscent of recently
described mirror-symmetric divisions in the developing neural tube
(Tawk et al., 2007). In addition, Pcdh1α antigenicity appears to be
present in nuclei; even in single optical sections (Figs. 2f–h), none of
the cells exhibit the "donut" staining pattern that would be consistent
with the distribution of a cell-surface membrane protein.
To characterize the nuclear distribution of Pcdh1α in more detail,
we co-labeled embryos for Pcdh1α and DAPI (Fig. 3a). Apart from the
extensive labeling of the longitudinal axon tracts, Pcdhα labeling
exhibits a nearly perfect overlap with DAPI (Fig. 3a). To further
investigate the distribution of the cytoplasmic domain, we expressed a
myc-Pcdh1αCD fusion protein in neurons in the spinal cord (Fig. 3b).
The soluble cytoplasmic domain acts as a space-ﬁlling marker, loading
the entire neuron. Single optical sections through the center of the
nucleus show that the myc-Pcdh1αCD is concentrated in the nucleus,
overlapping with the nuclear stain, DAPI (Fig. 3b). These results
support previous in vitro studies, which have shown nuclear
localization of the Pcdhα cytoplasmic domain (Bonn et al., 2007),
and demonstrate that this occurs in vivo during zebraﬁsh
development.
To provide a more detailed view of the distribution of Pcdh1α
within neurons, we wanted to express Pcdh1α-GFP fusion proteins.
The diversity of pcdh1α isoforms makes expression of GFP-fusion
proteins challenging, as the use of pan-neuronal or even neuron-
speciﬁc promoters to express a fusion-proteinwill most likely result in
misexpression of the speciﬁc isoform. This could mislocalize the GFP-
fusion proteins within the cell. Therefore, we wanted an alternative
method to characterize the distribution of Pcdh1α protein in living
embryos. To do this, we obtained a 159 kb BAC clone that contained
the entire pcdh1α gene, including all 10 variable exons and the 3
constant exons. Using BAC recombineering, we placed GFP at the
carboxy-terminus of the pcdh1α constant cytoplasmic domain,
thereby tagging the entire cluster (Fig. 4a). We ﬁrst fused GFP, in
frame, to the full pcdh1α constant cytoplasmic domain to produce
Pcdh1αCD-GFP. We then replaced constant exon 1 with the
Pcdh1αCD-GFP fusion, thus preserving the splice acceptor site (Fig.
4a). Each of the variable exons should be spliced onto this Pcdh1αCD-
GFP to generate native, full length Pcdh1α-GFP fusion proteins (Fig.
4b). Injection of the modiﬁed BAC yielded embryos that mosaically
expressed GFP-tagged Pcdh1α (Figs. 4c, d). All of the GFP-tagged
proteins should be expressed in a cell-type appropriate manner, as
each individual isoform is expressed under the inﬂuence of its native
promoter/enhancer network. Tagging the constant cytoplasmic
domain does not distinguish between isoforms, but provides an
overall view of Pcdh1α protein distribution within neurons.
In 24–30 hpf embryos, cell bodies of neurons labeledwith Pcdh1α-
GFP exhibited both nuclear and perinuclear staining (Fig. 4c). In
addition, Pcdh1α-GFP strongly labeled axons, was distributed diffu-
sely along the axon (Figs. 4c, d), and was concentrated in the growth
cone (Fig. 4e). In addition, we observed small, discrete puncta along
the axons (Fig. 4d). Time-lapse anslysis revealed that these puncta
were mobile, transport organelles (Fig. 4f; Supplemental Movie 1),
Fig. 2. Whole-mount immunocytochemistry of Pcdh1α. (A) A rabbit polyclonal antibody was raised against the constant intracellular domain of Pcdh1α protein. To test the
antibody speciﬁcity, we expressed a membrane-associated Pcdh1αCD-GFP in HEK293 cells. Cellular extracts from untransfected cells (lane 1) and transfected cells (lane 2) were
prepared for SDS-PAGE and probed with the afﬁnity-puriﬁed Pcdh1αCD antibody. No immunoreactivity was detected in untransfected cells, but a strong band of the predicted
mass (~76 kDa) was detected in transfected cells. We also prepared protein extracts from 72 hpf embryos (lane 3) and detected a doublet of ~105 kDa (asterisk), which are the
masses predicted for pcdh1α isoforms. (B) HEK293 cells were transfected with the membrane-targeted Pcdh1αCD-GFP, ﬁxed, and stained using the Pcdh1αCD antibody.
Immunolabeling with Pcdh1αCD antibody (red) overlaps strongly with Pcdh1α-GFP (green) in transfected cells, but does not label untransfected cells. DAPI is shown in blue. (C-H)
Immunolabeling with Pcdh1αCD antibody is consistent with the in situ hybridization data, as the antibody labels developing neuronal clusters and the early axonal scaffold (C and
D). Distinct clusters of neurons can be visualized in the hindbrain (D and E), as can neurons of peripheral ganglia (E). In the spinal cord, axons can be observed in the tracts of the
marginal zone (arrows in panel F), in addition to the lateral columns of neurons. In the ventral spinal cord (G), cells are frequently observed close to the midline (arrows), and often
appear in pairs, suggesting that Pcdh1α expression turns on upon differentiation, shortly after the terminal cell division. (H) Lateral view of the spinal cord at 28 hpf. A consistent
feature of neurons (E–H) is labeling throughout the cell body, demonstrating that Pcdh1αCD is not excluded from the nucleus. Panels C–E are maximum intensity projections of
image stacks, and panels F–H are single optical sections. AC, anterior commissure; A/V, acoustico-vestibular; cb, cerebellum; di, diencephalon; ep, epiphysis; hb, hindbrain; hy, hy-
pothalamus; pLLg, posterior lateral line ganglion; POC, postoptic commissure; r2–r6, rhomobomeres 2–6; ret, retina; SC, spinal cord; SOT, supraoptic tract; tec, tectum; teg, tegmen-
tum; tel, telencephalon; Tg, trigeminal ganglion; TPC, tract of the posterior commissure.
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Fig. 3. Pcdh1α intracellular domain is present in the nucleus. (A) Shown are dorsal views of the spinal cord from 24 hpf embryos; images are maximum intensity projections of two
adjacent optical sections (1 μm spacing). The left panel shows DAPI labeling of cells. The middle panel shows the same ﬁeld stained with antibody against Pcdh1αCD. The right panel
is an overlay showing that Pcdh1α immunoreactivity is present in neuronal nuclei. (B) The leftmost panel is a maximum intensity projection of a spinal interneuron that has been
labeled with amyc-tagged Pcdh1αCD. Themyc-Pcdh1αCD fusion is distributed throughout the neuron. Themiddle two panels show single optical sections through the same neuron.
The center-left panel shows staining of nuclei with DAPI and the center-right panel shows anti-myc immunolabeling. The myc-Pcdh1αCD is enriched in the nucleus. The overlay of
the two ﬂuorescence images is shown in the panel on the right. Scale bar=10 μm.
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GFP (Jontes et al., 2004). However, unlike N-cadherin-GFP, we did not
observe any stable accumulations of Pcdh1α-GFP that would indicate
an enrichment at synapses at these early stages of synaptogenesis.
The distribution of Pcdh1α-GFP along the axon differed consider-
ably from what has previously been demonstrated for the synaptic
adhesion molecule N-cadherin-GFP (Jontes et al., 2004). Most
hypotheses regarding the function of Pcdhα assume or postulate
that they are synaptic adhesion molecules. While they exhibit only
minimal activity in traditional in vitro adhesion assays (Morishita et
al., 2006; Triana-Baltzer and Blank, 2006), some evidence suggests
that Pcdhα is enriched at synapses (Kohmura et al., 1998). To further
characterize the extent of synaptic accumulation of Pcdh1α, we
performed whole-mount immunocytochemistry on 28 hpf embryos
(Fig. 5). First, we double-labeled embryos with antibodies against
Pcdh1α and the presynaptic marker, SV2 (Fig. 5a). Even in early
embryos, the density of axons and synapses in the spinal cord is high,
making it difﬁcult to meaningfully assess colocalization, due to an
excessive overlap of ﬂuorescence signal among neighboring axons.
However, in cases where isolated segments of axon could be
discerned, Pcdh1α did not overlap signiﬁcantly with SV2 puncta
(Fig. 5a). In ﬁxed tissue, the distribution of Pcdh1α-GFP appeared
more discontinuous than in living embryos, possibly due to an artifact
of ﬁxation or permeabilization. However, Pcdh1α-GFP was mostly
continuous along axons, and did not co-vary with SV2 staining (Fig.
5b). Our results indicate that Pcdh1α, though present throughout the
axon, is not enriched in stable, synaptic puncta at these early
developmental stages.
Antisense morpholino inhibition of Pcdh1α results in neuronal apoptosis
To investigate the in vivo function of the pcdh1α gene, we designed
splice-blocking antisense morpholino oligonucleotides (Draper et al.,
2001; Nasevicius and Ekker, 2000) against the constant exons of the
pcdh1α gene (Fig. 6). Speciﬁcally, we targeted the donor splice
junction of the ﬁrst constant exon (c1; Fig. 6a). Targeting of this splice
junction is predicted to have two possible outcomes. In the ﬁrst case,
the downstream intron could be included, which results in a stop
codon just downstream of the c1 exon (Fig. 6b outcome 1).
Alternatively, the c1 exon may be deleted, with the variable exon
splicing directly to the c2 exon, which would place the c2 exon out offrame and result in a stop codon shortly after the end of the variable
exon (Fig. 6b outcome 2). In either case, the protocadherin protein
would be truncated, lacking an intact cytoplasmic domain. Disruption
of constant exon splicing should affect processing of all variable
isoforms of the targeted gene, thus inhibiting the function of the entire
cluster. To assess the effect of morpholino injection, we prepared total
RNA from pcdh1α-morpholino-injected and performed RT-PCR, using
primers designed to test for the presence of the predicted, aberrant
splice products. We found that pcdh1α-morpholino-injection never
completely blocked the production of full length, wild type transcript
(Fig. 6c). However, both of the major, predicted products of mis-
splicing were observed. Cloning and sequencing of these PCR products
conﬁrmed our predictions (data not shown). Although our RT-PCRwas
not quantitative, gel densitometry suggested that the two mis-spliced
species accounted forN60% of the pcdh1α transcript (b40% native
transcript). We also used Western blot analysis to determine the
extent of protein loss (Fig. 6d). As shown in Fig. 2a, the Pcdh1αCD
antibody recognizes a doublet ~105 kDa in 24 and 48 hpf zebraﬁsh
extracts. Injection of pcdh1α-morpholinos reduced the intensities to
~26% at 24 hpf and ~18% at 48 hpf, but never completely eliminated
intact Pcdh1α protein (Fig. 6d).
Having characterized the effects of our morpholinos at the
molecular level, we wanted to determine their effects on neural
development. The primary phenotype associated with pcdhγ-−/− mice
is neurodegeneration in the spinal cord (Wang et al., 2002b). To see if
inhibition of pcdh1α had a similar phenotype, we used TUNEL to
characterize cell death in 24 hpf embryos (Fig. 7). After injection of
2.5 ng of the splice-blocking pcdh1α-morpholinos, embryos exhibited
evidence of extensive apoptosis throughout the nervous system (Fig.
7a). This phenotype was observed for either of two, distinct
morpholinos (MO1.1 or MO1.2), but not for 5 basepair mis-match
controls for either morpholino (Figs. 7a, d). As it has recently been
reported that 15–20% of morpholino oligonucleotides can result in cell
death due to off-target activation of p53 (Robu et al., 2007), wewanted
to ensure that our observed phenotype was speciﬁcally due to
inhibition of pcdh1α. Therefore, we co-injected 5 ng of p53
morpholino (p53MO) with 2.5 ng of either MO1.1 or MO1.2. In neither
case did we observe an attenuation of the cell death phenotype (Figs.
7a, c). As a further test of morpholino speciﬁcity, we co-injected sub-
threshold amounts of MO1.1 and MO1.2 (1 ng each). When injected
individually, these levels did not result in signiﬁcant amounts of
Fig. 4. Pcdh1α-GFP expression by BAC recombineering. (A) The organization of the pcdh1α gene in the original (top) and recombineered (bottom) BACs. (B) Each variable exon
consists of a signal sequence (S), 6 cadherin repeats, a transmembrane segment (T) and a very short portion of the cytoplasmic domain (CD). Each of these is spliced to the Pcdh1αCD-
GFP to generate GFP-tagged proteins that are full length protocadherins. (C) Neurons labeled in the spinal cord of a ~28 hpf embryo. Pcdh1α-GFP exhibits both nuclear and
perinuclear staining and strongly labels axons. Scale bar=10 μm. (D) Axonal labeling is largely diffuse and continuous, although small puncta are occasionally present (arrows). (E)
Pcdh1α-GFP is enriched in the central core of axonal growth cones, and is likely concentrated in intracellular organelles. Scale bar=8 μm. (F) Mobile transport organelles can be
visualized using time-lapse microscopy. These transport packets have similar properties to transport packets previously observed both in vitro and in vivo. Scale bar=10 μm.
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cell death (Fig. 7c). This further indicated that the neuronal apoptosis
did not result from non-speciﬁc effects of the injected morpholinos,
but was instead a consequence of inhibiting pcdh1α function. In
embryos with less severe phenotypes, a rhombomeric pattern to the
cell death can be observed in the hindbrain (Fig. 7b), whichcorresponds to the pattern of expression observed both by in situ
hybridization (Fig. 1) and by antibody labeling (Fig. 2). We have
observed similar results with morpholinos against the pcdh2α cluster
(Supplementary Fig. 1).
Due to the complex genomic organization of the pcdh1α gene, it
was difﬁcult to perform a routine rescue experiment. Because our
Fig. 5. Pcdh1α does not colocalize with presynaptic markers. (A) Maximum intensity projections of 3 adjacent optical sections (spacing is 1 μm) were generated in order to
reconstruct an extended region of labeled axon tracts in the spinal cord of a 24 hpf embryo. The top panel shows labeling with antibody against Pcdhα; the middle panel shows
staining with the presynaptic marker, SV2; the bottom panel shows the overlay. The panels on the right are magniﬁed views of the boxed regions. Although both SV2 and Pcdh1α
antibodies label many of the same axons, the staining patterns are distinct with Pcdhα failing to exhibit punctate staining that overlaps with SV2. Scale bar=25 μm. (B) Shown are
maximum intensity projections of 2 adjacent optical sections (spacing is 0.5 μm). The top panel shows a segment of axon labeled with Pcdhα-GFP, which was then processed for
whole-mount immunocytochemistry. In general, the labeling of Pcdhα-GFP in ﬁxed tissue appears more discontinuous than in living embryos. The middle panel shows the same
ﬁeld, which has been labeled with SV2 antibodies. Although the discontinuity of Pcdhα-GFP labeling has an almost punctate appearance, it does not signiﬁcantly overlap, or co-vary,
with the punctate SV2 labeling. Scale bar=8 μm.
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common cytoplasmic domain, we asked whether expressing the
soluble cytoplasmic domain alone could attenuate the cell death
phenotype. We injected embryos with 2.5 ng of MO1.1, 200 pg myc-
αCD mRNA or both (Fig. 8). For each group, embryos were scored as
exhibiting wild-type/mild, moderate or severe levels of apoptosis, as
assessed by acridine orange staining (Fig. 8a). Embryos that were
injected with the soluble myc-αCD mRNA appeared morphologically
normal, but did exhibit a small elevation in levels of cell death.
However, when co-injected with MO1.1 (Fig. 8b), the myc-αCD
signiﬁcantly attenuated neuronal apoptosis (26% severe) in compar-
ison to injection of morpholino alone (51% severe; pb0.05, Student's
t-test). Co-injected embryos exhibited a shift toward a milder cell
death phenotype, indicating that expression of the Pcdh1α cytoplas-
mic domain can partially compensate for the loss-of-function due to
our splice-blocking morpholinos. This effect was found to be dose-
dependent (Fig. 8c).To determinewhether the observed loss of neurons was general, or
speciﬁc only to particular neuronal subsets, we performed whole-
mount immunocytochemistry using antibodies against the axonal
marker acetylated-tubulin. We collected image stacks through the
spinal cord of 28 hpf embryos (between segments 5 and 10), and
generated maximum intensity projections of either the dorsal spinal
cord, containing Rohon–Beard cells, or the ventral spinal cord,
containing the ventral tracts and commissures (Fig. 9). Pcdh1α-
morpholino-injected embryos exhibited a comparable number of
Rohon–Beard sensory neurons to wild type embryos (2–3/hemiseg-
ment; Figs. 9a, c), with no obvious defects in the size or arborization of
their peripheral sensory axons (data not shown). Similarly, the
number of CaP (Caudal Primary) motor axons extending into ventral
muscle was also unaltered in pcdh1α-morpholino-injected embryos
(1/hemisegment; Figs. 9b, c). In contrast, we observed a signiﬁcant
loss of commissural axons (wild type, 62±6 axons (mean±SEM);
MO1.1, 42±5 axons; pb0.05, Student's t-test), indicating a reduced
Fig. 6. Antisense morpholinos block splicing of pcdh1α. (A) Schematic diagram showing the strategy for disrupting pcdh1α, using splice-blocking morpholinos. The red and blue bars
show the relative positions of MO1.1 and MO1.2, respectively. (B) Schematic describing the predicted outcomes of our pcdh1α splice-blocking strategy. The labeled arrows indicate
the positions of our diagnostic PCR primers. (C) RT-PCR using RNA from morpholino injected embryos. Lane a/1 shows two bands, the upper is representative of wildtype mRNA, in
which splicing has occurred properly. The lower band reﬂects the deletion of constant exon 1, in which the pcdh1α variable exons have been spliced directly to constant exon 2.
Constant exon 2 and the variable exons are in different reading frames, resulting in a stop codon shortly after the end of the variable exons (variant 1 in panel B). Lane a/2 shows a
band that results from the inclusion of the C1/C2 intron. This product is also truncated, with a stop codon occurring shortly after the end of constant exon 1 (variant 2 in panel B). In
this experiment, aberrantly spliced variants account for N60% of the detected transcripts. (D) To assess the degree of protein loss in response to morpholino injections, we performed
Western blots at 24 and 48 hpf. The levels of both bands of the doublet are decreased in response toMO1.1 morpholino injection. At 24 hpf, the levels of Pcdhαwere reduced to ~26%
of wild type levels, while at 48 hpf, the levels were reduced to ~18%.
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observed in the nervous system of pcdh1α-morpholino-injected
embryos affects only subsets of neurons. To further conﬁrm the effect
of expressing myc-αCD in attenuating the effects of morpholinos, we
counted the number of labeled commissural axons in the spinal cords
of 23 hpf embryos that had been injectedwithmyc-αCDmRNA, MO1.1
or both (Fig. 9e). As was the case in older embryos, there was a
signiﬁcant loss of axons in the morpholino-injected embryos (mRNA,
37.5±1.4 axons (mean±SEM); MO1.1, 29.8±1.8 axons; pb0.01, Stu-
dent's t-test). When mRNA and morpholino were co-injected, we
observed a small recovery in the number of axons (32.5±2 axons,
mean±SEM).
Discussion
The zebraﬁsh offers considerable experimental advantages for the
study of neural development, and we have begun to exploit these to
investigate the function of pcdh1α in vivo. Both of the pcdhα genes in
zebraﬁsh are broadly expressed in neurons of the developing nervous
system, with in situ probes labeling all of the major subdivisions of the
CNS, clusters of cells in the peripheral nervous systemand the retina (Fig.
1). Whole-mount immunocytochemistry with an antibody against
Pcdh1αCD reveals a similar pattern, labeling neurons in the brain and
spinal cord, as well as the major axonal tracts (Fig. 2). The expression ofpcdh1α in sensory neurons, such as the trigeminal ganglion neurons,
suggests a primarily axonal or presynaptic function of Pcdh1α, as these
sensory neurons neither have dendrites, nor receive synaptic input. A
similar axonal distribution has previously been observed in chick ciliary
ganglion neurons (Blank et al., 2004). The distribution of Pcdh1αwithin
axons appears to be primarily continuous, and provides no support for a
synaptic enrichment of Pcdh1α (Figs. 4 and 5). This contrasts sharply
with the in vitro distribution of Pcdhγ proteins, which exhibit a punctate
distribution within neurons, present both at synapses and within
internal membranous organelles (Phillips et al., 2003). This difference
likely reﬂects a fundamental divergence in the cell biological role of these
two genes.
It has recently been demonstrated in cultured cells that Pcdhγ and
Pcdhα can undergo sequential proteolytic processing, ﬁrst by matrix
metalloproteases, then by Presenilin-1 (Bonn et al., 2007; Haas et al.,
2005; Hambsch et al., 2005). The result of these cleavages is a soluble
intracellular domain that can be translocated to the nucleus. However,
the relative amount of protocadherin that appeared to undergo
processing was small. In this study, it appears that early in
development a substantial fraction of endogenous Pcdh1α immunor-
eactivity is present in the nucleus, as determined by whole-mount
immunocytochemistry using an antibody against the cytoplasmic
domain (Fig. 3). The functional signiﬁcance of this nuclear localization
is uncertain, although it has been suggested that nuclear localization
Fig. 7. Pcdh1α splice-blocking morpholinos result in apoptosis throughout the CNS. (A) Shown here are 24 hpf embryos processed for TUNEL to assess levels of apoptosis. Wild type
and 5 basepair mismatch control morpholinos exhibited relatively little cell death at 24 hpf, as indicated by the lack of darkly stained nuclei. In contrast, pcdh1α-morpholino-injected
embryos (2.5 ng) showed a dramatic increase in labeled nuclei, which was not prevented by co-injection of 5 ng p53MO. Thus, the reduction in full-length Pcdh1α protein results in
neuronal death. The insets showmagniﬁed views of the boxed portion of the spinal cord. (B) Dorsal view of the hindbrain region in a pcdh1α-morpholino-injected embryo at 24 hpf.
Bilateral clusters of apoptotic cells can be observed that exhibit a rhombomeric pattern (arrows) that mimics the expression pattern determined by in situ hybridization and
immunocytochemistry. (C) Acridine orange staining was performed to score embryos for the cell death phenotype. We designed two different morpholinos against pcdh1α (MO1.1
and MO1.2), as well as 5 bp mismatch controls for each (MO1.1mis and MO1.2mis). Injection of 2.5 ng of either splice-blocking morpholino yielded extensive cell death in N90% of
injected embryos. Injection of control morpholinos failed to cause cell death. Co-injection of 5 ng of a p53 morpholino with 2.5 ng of either splice-blocking morpholino failed to
inhibit apoptosis, demonstrating that the cell death is not due to off-target activation of the p53 pathway. Injection of 1 ng of either MO1.1 or MO1.2 failed to cause a signiﬁcant
increase in apoptosis, while a combined dose of 1 ng of each morpholino resulted in a large increase in cell death.
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translocation of the cytoplasmic domain to the nucleus is involved in
gene regulation, it is not clear whether constitutive levels of
Pcdh1αCD would be required, or whether varying responses to
interactions at the cell surface might lead to a more dynamic
regulation of gene expression. However, it will be important to
demonstrate whether regulation of gene expression by either the
Pcdhα or Pcdhγ cytoplasmic domains occurs in vivo.
BACs are increasingly being used for the purpose of gene
expression in both mice and zebraﬁsh (Copeland et al., 2001; Heintz,
2001; Higashijima et al., 2004; Lee et al., 2001). The large amount of
genomic DNA present on BACs increases the spatial and temporal
control over transgene expression. In the case of protocadherin
proteins, which are differentially expressed within neuronal popula-
tions, ﬁdelity of expression is critical. We used BAC recombineering to
replace the ﬁrst constant exon of pcdh1α with an intact GFP-tagged
cytoplasmic domain (Fig. 4). Thus, each individual isoform is
expressed under the control of its own native promoter/enhancer
network, minimizing any potential artifacts due to misexpression of
an isoform in an inappropriate cell type. Neurons expressing Pcdh1α-
GFP exhibited both diffuse and punctate labeling along their axons
and cell bodies. The diffuse labeling appears to be due to a presence onthe plasma membrane, although a contribution from soluble
cytoplasmic domain (see above) cannot be ruled out. At these early
developmental timepoints, the punctate labeling is due to mobile
transport organelles (Fig. 4). These intracellular transport packets are
similar to those previously described for N-cadherin-GFP (Jontes et al.,
2004). In contrast to the case of N-cadherin-GFP, Pcdh1α-GFP does not
accumulate in stable puncta along the axon, further suggesting that
Pcdh1α is not enriched at synapses during the timeframe of our study.
In contrast to the strong labeling of axons by Pcdh1α-GFP, we did not
detect signiﬁcant staining of dendrites. This observation bolsters the
above conclusion that Pcdh1α may primarily play an axonal or
presynaptic role, and argues against a function in trans-synaptic
homophilic interactions.
Morpholino-based reduction in levels of full-length Pcdh1α
protein results in a dramatic increase in neuronal programmed cell
death. The speciﬁcity of this effect is argued by the following: 1) the
distribution of apoptotic neurons corresponds to the pattern of pcdh1α
expression (determined both by in situ hybridization and antibody
staining), 2) the observed phenotype requires only modest levels of
morpholino (2.5 ng), 3) targeting either of the two pcdhα clusters
yields similar phenotypes, 4) multiple morpholinos to a given pcdhα
gene yield similar results, 5) 5 basepair mis-match control
Fig. 8. Expression of Pcdh1α-cytoplasmic domain attenuates neuronal apoptosis. (A) Morpholino-injected embryos exhibit a range of phenotypes that we have grouped into wild
type/mild, moderate and severe, on the basis of density of apoptotic cells and embryo morphology. Shown are representative embryos for each group. (B) To assess the ability of the
Pcdh1α cytoplasmic domain to attenuate the apoptosis observed in response to Pcdh1α disruption, we injected either Pcdh1αCDmRNA (200 pg), MO1.1 (2.5 ng), or both together. By
itself, Pcdh1αCDmRNA resulted in a small increase in the number of embryos exhibiting moderate levels of apoptosis (n=190). Injection of MO1.1 resulted in an increase in embryos
exhibiting bothmoderate and severe levels of cell death (34%±6moderate, 51%±7 severe; mean±SEM; n=214). WhenMO1.1 and Pcdh1αCDmRNA are co-injected, the percentage of
embryos exhibiting a severe phenotype is dramatically decreased (51%±5 moderate, 27%±3 severe; mean±SEM; n=195; pb0.05, Student's t-test), indicating a shift toward milder
phenotypes. Thus, expression of the Pcdh1α cytoplasmic domain can attenuate the effects of morpholino injection. (C) In order to demonstrate the speciﬁcity of the myc-αCDmRNA
effects, we determined the dose-dependence of the observed attenuation of cell death. Embryos were injected with 2 ng of MO1.1 along with 0, 50, 100 or 200 pg of myc-αCDmRNA.
We found that 50 pg of mRNA had no discernible effect on the severity of cell death, but that 100 pg and 200 pg were increasingly effective in reducing the percentage of embryos
exhibiting a severe phenotype (0 pg mRNA: 51%, n=42; 50 pg: 52%, n=52; 100 pg: 41%, n=69; 200 pg: 27%, n=195).
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pathway does not inhibit the observed cell death (Robu et al., 2007),
and 7) only a subset of neurons are affected. Thus, reduction in cellular
levels of full-length Pcdh1α leads to neuronal apoptosis during early
development in zebraﬁsh. These observations are similar to the loss of
spinal interneurons in pcdhγ−/− mice (Wang et al., 2002b). While the
cell death observed in zebraﬁsh occurs relatively early in development,
the cell death observed in mice occurs well after neurons have already
extended axons and dendrites, and formed synapses (Wang et al.,
2002b). This may indicate that pcdhα and pcdhγ act by distinct
mechanisms, participate in distinct cellular processes, and/or function
at distinct times in neural development. These results argue that pcdhα
and pcdhγ may operate in parallel or coordinately, but should not be
considered an enlarged complement of essentially equivalent proteins.The proximate cause of the observed apoptosis is unknown. Our
approach does not necessarily reduce the levels of Pcdh1α, per se,
but does result in a large fraction of Pcdh1α protein that lacks a
cytoplasmic domain. This suggests that the death could be a
consequence of cytoplasmic signaling events downstream of any
cell surface interactions in which Pcdh1αmay participate. Part of this
signaling potential could be through the translocation of the
Pcdh1αCD to the nucleus. Interestingly, neuronal death can be
attenuated by over-expression of a soluble Pcdh1α cytoplasmic
domain (Fig. 9). The mechanism of this attenuation is not known, as
both a partial restoration of cytoplasmic interactions or translocation
to the nucleus and nuclear signaling are possible.
The neuronal death that is observed in pcdhγ−/− mice and in pcdh1α
morphant zebraﬁsh could indicate a primary role in promoting neuronal
Fig. 9. Pcdh1α splice-blockingmorpholinos result in loss of neuronal subsets. (A) Immunolabeling of eitherwild type or pcdh1α-morpholino-injected embryoswith amonoclonal antibody
against acetylated tubulin prominently labeled neuronal cell bodies and axons, including Rohon–Beard cells, which are large sensory neurons present in the dorsal spinal cord. These cells
extend elaborate sensory arbors, which innvervate the skin. Maximum intensity projections from optical sections of the dorsal spinal cord revealed the bilateral arrays of Rohon–Beard cells
and a portion of their sensory arbors. Pcdh1α-morpholino-injection did not lead to any signiﬁcant loss of Rohon–Beard cells, nor did it affect arborization of their sensory axons (C). (B)
Maximum intensity projections of the ventral spinal cord revealed longitudinal axon tracts, aswell as commissural axons. In addition, this view revealed the exit of CaPmotor axons from the
spinal cord at the ventral roots. In contrast to wild type embryos, pcdh1α-morpholino-injected embryos exhibited a loss of both longitudinal axons and commissural axons. However, there
was no difference in the number of CaPmotor axons. (C) As is apparent in (a) and b), therewas no difference in either the number of CaPmotoneurons or Rohon–Beard sensory neurons (32
spinal segments from 8 embryos for each data set). D, Therewas a substantial loss of commissural axons inpcdh1α-morpholino-injected embryos.Wild type embryos had an average of 62±
5.7 (mean±SEM, n=8 embryos) commissural axons within 4 spinal segments at 26 hpf. In a matched set of embryos injected with MO1.1, there were 42±4.6 (mean±SEM, n=8 embryos)
commissural axons per 4 spinal segments. This differencewas found to be statistically signiﬁcant (pb0.05, Student's t-test). (E) Expression of the soluble Pcdhα cytoplasmic domainpartially
attenuates the loss of commissural axons. Embryos were injectedwith PcdhαCDmRNA alone, MO1.1 alone orMO1.1 and PcdhαCDmRNAwere immunolabeled for acetylated-tubulin at 23
hpf. ThemRNA-injected embryos had an average of 37.5±1.4 (mean±SEM,n=8 embryos) labeled commissural axons per 4 spinal segments.Morpholino-injected embryos had an average of
29.75±1.8 (mean±SEM, n=8 embryos) axons. This differencewas statistically signiﬁcant (pb0.01, Student's t-test). Embryos injected bothwithmRNA andMO1.1 exhibited an intermediate
number of labeled axons, 32.5±2 (mean±SEM, n=8 embryos).
186 M.R. Emond, J.D. Jontes / Developmental Biology 321 (2008) 175–187survival, or could represent a secondary consequence of protocadherin
loss that is not directly related to the cellular role of either protocadherin
gene product. As has been suggested, the former possibility is analogous
to the role played by neurotrophins and their receptors (Wang et al.,
2002b). However, the cellular function of neither Pcdhα nor Pcdhγ has
been established. Synaptic deﬁcits have been identiﬁed, in vitro, in
neurons cultured from pcdhγ−/− mice, but the mechanism by which loss
of pcdhγ results in these deﬁcits has not been established, nor has a
relationship between this observation and the neuronal death. Further
investigation into the cell biology of Pcdhα and Pcdhγ during
development will be required in order to address the mechanisms
leading to neuronal death, and their signiﬁcance for neural development.
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